Barclays PLC increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 163.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,449 shares of the company's stock after purchasing an additional 163,005 shares during the quarter. Barclays PLC owned about 0.18% of MiMedx Group worth $1,550,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Isthmus Partners LLC raised its holdings in MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock worth $27,000 after purchasing an additional 91,714 shares during the last quarter. Blue Trust Inc. acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. bought a new stake in shares of MiMedx Group during the second quarter worth approximately $40,000. Point72 DIFC Ltd lifted its holdings in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after buying an additional 4,275 shares during the period. Finally, Entropy Technologies LP bought a new position in MiMedx Group in the third quarter valued at approximately $64,000. Institutional investors and hedge funds own 79.15% of the company's stock.
Analyst Ratings Changes
Separately, StockNews.com cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $12.00.
Read Our Latest Stock Analysis on MDXG
MiMedx Group Trading Up 0.3 %
Shares of NASDAQ:MDXG traded up $0.03 during mid-day trading on Friday, reaching $9.42. The stock had a trading volume of 787,494 shares, compared to its average volume of 749,499. The firm has a market cap of $1.38 billion, a PE ratio of 17.13 and a beta of 1.98. The firm has a 50 day simple moving average of $8.35 and a two-hundred day simple moving average of $7.17. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14.
About MiMedx Group
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Recommended Stories
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
